NCT04345913 2026-04-13
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT07494448 2026-03-27
JAZMINE
MedSIR
Phase 1/2 Not yet recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
NCT06942234 2025-09-17
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Recruiting
NCT00365157 2025-07-11
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05041101 2025-06-13
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated